Aromics

Focus: Aromics is an oncology-focused diagnostics and therapeutics company based in Barcelona, Spain, currently in early-stage clinical development.

Oncology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Aromics

AI assessmentNot Hiring

No open roles listed right now. Follow Aromics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AROG4-01

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06652529Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for Aromics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused oncology portfolio with dual therapeutics and diagnostics capability in a high-value therapeutic area
European base offers alternative pharma ecosystem exposure and potential EU regulatory pathway advantages
Ground-floor opportunity at pre-revenue biotech with early-stage pipeline still building intellectual property value

Watch Out For

Zero active job openings and no publicly disclosed hiring activity suggest limited near-term career entry points
Single Phase 1 program with no advanced-stage assets creates high clinical and financial risk with extended value realization timeline
Lack of disclosed funding, revenue, employee count, and financial data indicates either stealth mode or resource constraints that could threaten stability

Generated by Claude from Aromics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline